Last updated: August 1, 2026
Qelbree is Supernus Pharmaceuticals’ extended-release viloxazine product for attention-deficit/hyperactivity disorder (ADHD). The FDA approved Qelbree for pediatric patients aged 6 to 17 in April 2021 and expanded the indication to adults in April 2022.[1] Its commercial positioning rests on a nonstimulant mechanism, once-daily dosing, no controlled-substance scheduling and broad age coverage.
The principal commercial risks are competition from generic atomoxetine, low-cost stimulants, branded nonstimulants such as Intuniv and Strattera, payer restrictions, and the absence of a large established adult market share. Qelbree’s growth opportunity is strongest in patients who do not respond to or cannot use stimulant therapy.
What is Qelbree and how does viloxazine work?
Qelbree contains viloxazine hydrochloride in an extended-release formulation. The drug is approved for ADHD in patients aged 6 years and older.
Viloxazine is a norepinephrine reuptake inhibitor with activity at selected serotonin receptors. The FDA label does not classify Qelbree as a stimulant, and viloxazine is not a controlled substance under the federal Controlled Substances Act.[1]
FDA-approved age groups and dosing
| Patient group |
FDA status |
Typical starting dose |
Maximum labeled dose |
| Children 6-11 years |
Approved |
100 mg once daily |
400 mg once daily |
| Adolescents 12-17 years |
Approved |
200 mg once daily |
400 mg once daily |
| Adults |
Approved |
200 mg once daily |
600 mg once daily |
Qelbree capsules may be swallowed whole or opened and sprinkled over applesauce. The extended-release formulation is designed for once-daily administration.
The principal label warnings include suicidal thoughts or behavior, increased blood pressure and heart rate, activation of mania or hypomania, somnolence or fatigue, and drug interactions involving CYP1A2 and monoamine oxidase inhibitors.[1]
What clinical trials supported Qelbree approval?
Qelbree’s pediatric approval was supported by randomized, placebo-controlled trials in children and adolescents. The adult approval relied on placebo-controlled Phase 3 studies in adults with ADHD.
Pediatric clinical-trial program
The pediatric program evaluated children and adolescents across several age ranges and used changes in ADHD Rating Scale scores as the principal efficacy measure. Across the pivotal studies, viloxazine extended release produced statistically significant improvements compared with placebo.
The pediatric evidence base included:
- Children aged 6 to 11 years.
- Adolescents aged 12 to 17 years.
- Flexible-dose and fixed-dose study designs.
- Short-term efficacy trials, generally lasting approximately six to eight weeks.
- Open-label extension studies assessing longer-term exposure.
The main limitation is the short duration of the randomized efficacy trials. The longer-term evidence comes primarily from open-label extensions rather than randomized comparative studies.
Adult clinical-trial program
The adult indication was supported by Phase 3 trials that evaluated once-daily viloxazine ER over approximately six weeks. The studies reported statistically significant improvements in ADHD symptoms compared with placebo.
The adult trials included several dose levels, with efficacy observed across the studied dosing range. Common adverse events included insomnia, fatigue, nausea, decreased appetite, dry mouth and headache.[1]
Qelbree has not established superiority over stimulants or atomoxetine in head-to-head randomized trials. Its clinical value is therefore based on its nonstimulant profile, lack of controlled-substance status and use in patients for whom stimulant therapy is unsuitable.
What is the current Qelbree clinical-trial pipeline?
Qelbree’s core ADHD development program is substantially complete because the product has pediatric and adult FDA approval. Ongoing clinical work has focused on long-term safety, real-world use, postmarketing surveillance and potential commercial label expansion rather than a new pivotal indication.
The available development profile is:
| Development area |
Status |
| Pediatric ADHD, ages 6-17 |
FDA approved |
| Adult ADHD |
FDA approved |
| Long-term safety |
Supported by open-label extensions and postmarketing data |
| Comparative efficacy versus stimulants |
Not established |
| ADHD maintenance or relapse prevention |
No broad FDA label claim |
| Pediatric patients under age 6 |
Not FDA approved |
| Non-ADHD psychiatric indications |
No established FDA approval |
A significant future opportunity would be an indication below age six, but that would require a dedicated development program and additional FDA review. The under-six ADHD market is clinically relevant but carries greater safety, dosing and developmental risk.
How does Qelbree compare with competing ADHD drugs?
Qelbree competes in both the nonstimulant and broader ADHD markets.
| Product |
Active ingredient |
Class |
Controlled substance? |
Key competitive issue |
| Qelbree |
Viloxazine ER |
Nonstimulant |
No |
Newer product with payer and awareness barriers |
| Strattera |
Atomoxetine |
Nonstimulant |
No |
Generic competition and low price |
| Intuniv |
Guanfacine ER |
Alpha-2A agonist |
No |
Generic competition; sedation and blood-pressure effects |
| Adderall XR |
Mixed amphetamine salts ER |
Stimulant |
Yes |
Strong efficacy and broad physician familiarity |
| Vyvanse |
Lisdexamfetamine |
Stimulant |
Yes |
Strong brand history; generic competition after loss of exclusivity |
| Concerta |
Methylphenidate ER |
Stimulant |
Yes |
Established use and generic alternatives |
| Azstarys |
Serdexmethylphenidate/dexmethylphenidate |
Stimulant |
Yes |
Branded duration and delivery profile |
Qelbree’s strongest differentiation is the combination of once-daily dosing, nonstimulant pharmacology and no controlled-substance classification. Its main weakness is that many prescribers and patients still regard stimulants as the most effective first-line option.
What is Qelbree’s FDA regulatory and Orange Book status?
Qelbree is an FDA-approved prescription drug regulated under the New Drug Application pathway. The reference product is listed in the FDA Orange Book under viloxazine hydrochloride extended-release capsules.[2]
Qelbree does not receive the same market-access protection associated with controlled-substance products, because it is not scheduled. Its principal regulatory protection comes from the New Drug Application, listed patents, pediatric exclusivity and any applicable regulatory exclusivities.
The FDA approval dates are:
| Milestone |
Date |
| Pediatric approval, ages 6-17 |
April 26, 2021 |
| Adult approval |
April 26, 2022 |
The pediatric approval generated six months of pediatric exclusivity under the Hatch-Waxman framework. That period has expired. Adult approval did not create a new five-year NCE exclusivity period because the adult indication was added to an existing product approval.
What patents protect Qelbree and when does it lose exclusivity?
Qelbree’s commercial protection is expected to depend primarily on formulation and extended-release delivery patents rather than composition-of-matter protection for viloxazine itself. Viloxazine was previously marketed in Europe under the name Vivalan, which limits the likelihood that the active ingredient receives a new U.S. chemical-entity exclusivity period.
The relevant protection categories are:
- Extended-release viloxazine formulations.
- Dosage forms and release-control technologies.
- Manufacturing and pharmaceutical-composition claims.
- Method-of-use claims for ADHD.
- FDA Orange Book-listed patents covering the approved product.
The commercial timing is more complex than a single expiration date. A generic applicant may challenge one or more listed patents through an Abbreviated New Drug Application and Paragraph IV certification. The earliest lawful entry date would depend on patent validity, infringement findings, statutory stays, settlements and any authorized-generic arrangement.
How strong is the Qelbree patent estate?
Qelbree’s patent estate appears commercially meaningful but structurally narrower than an estate based on a new chemical entity. Formulation patents can delay generic entry if the claims cover the marketed release profile and cannot be designed around economically. They are usually more vulnerable than composition-of-matter claims because generic developers can pursue alternative release mechanisms or dosage forms.
Method-of-use patents may support litigation but are less effective against skinny-label generic launches if the generic label omits the patented use. Manufacturing patents can raise development costs but may not block a non-infringing generic process.
A credible generic-entry analysis requires review of the current Orange Book listing, patent family prosecution history, claim scope, terminal disclaimers and any Paragraph IV litigation. The expected risk is therefore higher than for a drug with an unexpired composition-of-matter patent.
Which companies are challenging Qelbree?
No major publicly established Qelbree Paragraph IV challenger or final court judgment had materially changed the product’s market position through June 2024. Generic competition remains a medium-term risk because viloxazine is an older active ingredient and Qelbree’s principal differentiation comes from its extended-release formulation.
Potential challengers would likely include large generic manufacturers with ADHD portfolios and specialized formulation companies. The most important indicators will be:
- A Paragraph IV notice to Supernus.
- An ANDA litigation complaint filed within 45 days.
- A tentative or final FDA approval.
- A settlement that specifies a licensed launch date.
- A generic product with an alternative extended-release formulation.
What litigation and settlement issues affect Qelbree?
The primary legal exposure is Hatch-Waxman litigation over Orange Book-listed formulation, dosage-form or method-of-use patents. A Paragraph IV notice would trigger a 30-month FDA approval stay if Supernus filed suit within the statutory period.[3]
A settlement could permit an earlier generic launch in exchange for a license, supply arrangement or other commercial terms. No material public Qelbree settlement had been established as of June 2024.
Patent disputes involving other Supernus products do not automatically apply to Qelbree. Qelbree-specific risk should be assessed from the product’s own Orange Book entries and ANDA litigation record.
What is Qelbree’s market position and revenue exposure?
Supernus markets Qelbree alongside Oxtellar XR and other CNS products. Qelbree is strategically important because it gives Supernus exposure to the large ADHD market and extends the company beyond epilepsy and seizure-related therapies.
The addressable market is substantial, but branded revenue conversion depends on:
- Commercial insurance coverage.
- Prior-authorization requirements.
- Copay support.
- Physician familiarity.
- Use after stimulant failure or intolerance.
- Persistence during titration.
- Competition from inexpensive generic nonstimulants.
Qelbree’s revenue trajectory is more likely to follow gradual share capture than rapid category displacement. The product can gain prescriptions from patients with stimulant-related appetite suppression, insomnia, cardiovascular concerns, misuse risk or inadequate response. Payers may still require generic atomoxetine or guanfacine before covering Qelbree.
Commercial revenue scenarios
| Scenario |
Market assumption |
Revenue outlook |
| Downside |
Generic nonstimulants dominate; payers restrict Qelbree; limited adult uptake |
Low growth or decline before patent expiry |
| Base case |
Continued pediatric adoption and gradual adult penetration |
Moderate annual growth |
| Upside |
Strong nonstimulant positioning, improved payer access and broader prescriber adoption |
High single-digit to low double-digit growth before generic entry |
The largest revenue risk is not immediate biosimilar competition. Qelbree is a small-molecule drug, so biosimilars do not apply. The relevant threat is conventional ANDA-based generic competition.
What generic launch scenarios exist for Qelbree?
Three launch outcomes are commercially plausible:
Launch after patent expiry
A generic enters after all enforceable patents expire. This is the lowest-litigation scenario and normally produces rapid price erosion if multiple manufacturers launch.
Paragraph IV launch after litigation
A generic launches after prevailing in patent litigation, obtaining a court ruling of invalidity, unenforceability or non-infringement. This can compress the reference product’s revenue rapidly.
Settlement-based entry
Supernus and a generic manufacturer agree to an entry date before the latest patent expiry. The commercial impact depends on whether the settlement permits one generic or several entrants and whether the parties establish supply or authorized-generic terms.
Qelbree’s extended-release technology may slow substitution if generic products do not match prescriber expectations, but FDA-approved therapeutic substitution and payer formularies can still drive rapid conversion.
How does Qelbree compare with other branded nonstimulants?
Qelbree has a stronger age-range position than some competing nonstimulants because it is approved for both children and adults. Its once-daily formulation also supports adherence. Strattera and Intuniv benefit from longer clinical histories and generic availability, which lowers cost but reduces branded commercial value.
Qelbree has no controlled-substance scheduling advantage over Strattera or Intuniv. Its differentiation is instead based on pharmacology, tolerability, dosing and the ability to provide a nonstimulant option without using an older generic product.
Key Takeaways
- Qelbree is FDA approved for ADHD in children, adolescents and adults.
- The active ingredient is viloxazine extended release, a nonstimulant therapy.
- The product’s main commercial advantages are once-daily dosing and no controlled-substance scheduling.
- Pediatric and adult pivotal trials demonstrated statistically significant symptom improvement versus placebo, but no superiority over stimulants has been established.
- Generic atomoxetine, guanfacine and stimulant products create substantial pricing pressure.
- Qelbree’s patent protection is likely centered on extended-release formulation and related claims rather than a new chemical-entity patent.
- The principal legal risk is an ANDA Paragraph IV challenge to Orange Book-listed patents.
- Biosimilar competition is irrelevant because Qelbree is a small-molecule drug.
- The base-case commercial outlook is moderate growth, with long-term revenue dependent on payer access, adult adoption and the timing of generic entry.
- Qelbree’s value is highest in patients who do not respond to stimulants or cannot use controlled substances.
FAQs
Is Qelbree a stimulant?
No. Qelbree is an extended-release viloxazine nonstimulant approved for ADHD.
Can adults take Qelbree?
Yes. The FDA approved Qelbree for adults in April 2022, with a labeled maximum dose of 600 mg once daily.[1]
Does Qelbree have abuse potential like Adderall?
Qelbree is not a controlled substance and does not carry the same federal scheduling requirements as amphetamine or methylphenidate products.
Will Qelbree have biosimilars?
No. Biosimilars apply to biologic products. Qelbree is a small-molecule drug, so any future competitors would generally use the generic-drug ANDA pathway.
What is the biggest commercial threat to Qelbree?
The largest threat is generic and branded ADHD competition combined with payer restrictions. Generic atomoxetine and guanfacine can provide lower-cost nonstimulant alternatives, while stimulants remain the dominant efficacy benchmark.
References
-
U.S. Food and Drug Administration. (2024). Qelbree (viloxazine hydrochloride) extended-release capsules: Prescribing information. FDA.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
-
U.S. Food and Drug Administration. (2017). Abbreviated new drug application submissions: Refuse-to-receive standards. FDA.
-
Supernus Pharmaceuticals, Inc. (2024). Annual report on Form 10-K for the fiscal year ended December 31, 2023. U.S. Securities and Exchange Commission.
-
ClinicalTrials.gov. (2024). Studies of viloxazine extended release in patients with attention-deficit/hyperactivity disorder. U.S. National Library of Medicine.
